Praxis Precision Medicines (PRAX) Competitors $45.99 -0.93 (-1.98%) Closing price 04:00 PM EasternExtended Trading$46.02 +0.02 (+0.05%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRAX vs. AKRO, TLX, PTCT, LNTH, APLS, MLTX, PTGX, MIRM, MENS, and MTSRShould you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Akero Therapeutics (AKRO), Telix Pharmaceuticals (TLX), PTC Therapeutics (PTCT), Lantheus (LNTH), Apellis Pharmaceuticals (APLS), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), Mirum Pharmaceuticals (MIRM), Jyong Biotech (MENS), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry. Praxis Precision Medicines vs. Its Competitors Akero Therapeutics Telix Pharmaceuticals PTC Therapeutics Lantheus Apellis Pharmaceuticals MoonLake Immunotherapeutics Protagonist Therapeutics Mirum Pharmaceuticals Jyong Biotech Metsera Akero Therapeutics (NASDAQ:AKRO) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends. Which has more volatility & risk, AKRO or PRAX? Akero Therapeutics has a beta of -0.28, meaning that its stock price is 128% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.62, meaning that its stock price is 162% more volatile than the S&P 500. Which has stronger valuation and earnings, AKRO or PRAX? Praxis Precision Medicines has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$252.06M-$2.00-23.47Praxis Precision Medicines$8.55M113.23-$182.82M-$12.29-3.74 Do analysts rate AKRO or PRAX? Akero Therapeutics currently has a consensus target price of $81.57, indicating a potential upside of 73.78%. Praxis Precision Medicines has a consensus target price of $85.88, indicating a potential upside of 86.73%. Given Praxis Precision Medicines' higher possible upside, analysts plainly believe Praxis Precision Medicines is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Praxis Precision Medicines 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media refer more to AKRO or PRAX? In the previous week, Akero Therapeutics had 1 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 10 mentions for Akero Therapeutics and 9 mentions for Praxis Precision Medicines. Akero Therapeutics' average media sentiment score of 1.61 beat Praxis Precision Medicines' score of 0.80 indicating that Akero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akero Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Praxis Precision Medicines 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AKRO or PRAX more profitable? Akero Therapeutics has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -2,137.48%. Akero Therapeutics' return on equity of -15.84% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -15.84% -14.59% Praxis Precision Medicines -2,137.48%-60.07%-54.84% Do institutionals and insiders have more ownership in AKRO or PRAX? 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 7.1% of Akero Therapeutics shares are owned by insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryAkero Therapeutics beats Praxis Precision Medicines on 9 of the 15 factors compared between the two stocks. Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAX vs. The Competition Export to ExcelMetricPraxis Precision MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$987.47M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.01%P/E Ratio-3.747.3622.5622.49Price / Sales113.23398.26463.84113.07Price / CashN/A44.6737.7359.36Price / Book2.398.0910.046.68Net Income-$182.82M-$54.08M$3.27B$265.59M7 Day Performance-0.84%2.25%3.17%3.42%1 Month Performance-17.36%3.41%4.34%1.09%1 Year Performance-9.93%18.61%44.12%23.84% Praxis Precision Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRAXPraxis Precision Medicines1.7013 of 5 stars$45.99-2.0%$85.88+86.7%-12.3%$987.47M$8.55M-3.74110AKROAkero Therapeutics4.0891 of 5 stars$48.59-1.6%$81.57+67.9%+83.1%$3.95BN/A-24.3030News CoverageTLXTelix PharmaceuticalsN/A$11.90+3.1%$22.33+87.7%N/A$3.91B$516.72M0.00N/AAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumePTCTPTC Therapeutics4.3235 of 5 stars$49.80+2.0%$70.15+40.9%+40.9%$3.88B$806.78M7.141,410LNTHLantheus4.7628 of 5 stars$55.97+3.3%$105.50+88.5%-47.9%$3.68B$1.52B14.89700Analyst RevisionAPLSApellis Pharmaceuticals4.14 of 5 stars$27.35-1.4%$34.12+24.7%-28.7%$3.50B$781.37M-15.03770MLTXMoonLake Immunotherapeutics1.8419 of 5 stars$53.73-1.2%$74.43+38.5%+18.1%$3.49BN/A-19.332PTGXProtagonist Therapeutics1.892 of 5 stars$56.21+0.2%$67.20+19.6%+45.4%$3.49B$434.43M80.30120News CoveragePositive NewsMIRMMirum Pharmaceuticals3.4412 of 5 stars$66.68-1.8%$74.13+11.2%+68.7%$3.41B$336.89M-55.11140Positive NewsAnalyst DowngradeMENSJyong BiotechN/A$41.50-7.2%N/AN/A$3.40BN/A0.0031MTSRMetseraN/A$32.39+4.0%$55.00+69.8%N/A$3.27BN/A0.0081News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Akero Therapeutics Competitors Telix Pharmaceuticals Competitors PTC Therapeutics Competitors Lantheus Competitors Apellis Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors Protagonist Therapeutics Competitors Mirum Pharmaceuticals Competitors Jyong Biotech Competitors Metsera Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access